| |
Apply advanced AI/ML methodologies to improve equity through data-informed site selection. Learn how to meet your enrollment diversity goals in this new insight brief — Download now. 
|
|
|
Patient perspectives, priorities, and preferences – without these criteria, designing truly patient-centric rare disease trials is impossible. Turn up the volume of the patient voice on your next study with the help of our guide. 
|
|
| By Zoey Becker The agency flagged multiple observations at the company's Patheon CDMO subsidiary's Greenville, North Carolina, plant after a May inspection. |
|
|
|
By Darren Incorvaia To find RNA viruses hiding in genomic “dark matter,” researchers took advantage of one thing they all have in common: the RNA polymerase enzyme. |
By Kevin Dunleavy Four days after a compounding industry group filed a lawsuit against the FDA for removing Eli Lilly’s tirzepatide products from its shortage list, the U.S. regulator is taking a second look at its decision. |
By Nick Paul Taylor Sanofi has stopped a phase 2 trial of the Denali Therapeutics-partnered oditrasertib in multiple sclerosis. The French drugmaker tore the RIPK1 inhibitor trial from its list of active studies after failing to meet its primary and secondary endpoints, dealing a further blow to a collaboration with a troubled history. |
|
Wednesday, October 23, 2024 | 11am ET / 8am PT Large, deeply characterized patient cohorts are one of the most promising data resources today for understanding disease biology and developing new medicines. Join us as we explore how this data is driving the next generation of pharmaceutical development. Learn how to leverage genetic research in today's highly competitive landscape. Register now. 
|
|
By Gabrielle Masson Johnson & Johnson is jettisoning several programs, with three of the culls taking place in the neuroscience field. |
By Kevin Dunleavy For the second time in six months, the FDA approved a Pfizer treatment for hemophilia. On Friday the U.S. regulator signed off on Hympavzi, an anti-tissue factor pathway inhibitor for patients age 12 and older with hemophilia A or B. |
By Conor Hale CMR Surgical obtained a de novo clearance from the FDA for its Versius surgical system, allowing its modular laparoscopic robot to enter U.S. shores. |
By Zoey Becker The company picked up a record $3 billion in quarterly sales for its multiple myeloma powerhouse Darzalex as it grooms Tremfya to take on Stelara's market dominance. |
By James Waldron A phase 2 combination COVID-flu vaccine trial wrapped up in July 2023, with the “spontaneous” report of a patient developing motor neuropathy received last month. |
By Andrea Park A new campaign from Opella, Sanofi’s consumer health unit, is a royal flush. |
Fierce podcasts Don’t miss an episode |
| This week on "Podnosis," reporters discuss HIV’s impact in the South, inequitable access to PrEP and share stories from affected patients. |
|
|---|
|
|
|
Tuesday, October 29, 2024 | 10am ET / 7am PT Join us for this webinar to dive into the optimization of transient transfection scale-up. Don’t miss this opportunity to enhance your scale-up processes with new solutions. Register now to secure your spot! 
|
|
eBook Need the superpowers to select the right lab equipment? Sponsored by: PHC Corporation of North America |
Whitepaper Take a brief journey through some of the efforts that Lonza has made to optimize the manufacturability of bsAbs and other formats, and take a glance towards future directions with an emphasis on the upstream aspects. Sponsored by: Lonza |
Whitepaper How can an emerging company attract the right partner for a therapeutic asset (& optimize its value in a transaction)? This paper offers some insights. Presented by: Blue Matter |
Whitepaper Cognizant, in partnership with Microsoft, have interviewed 200 medtech decision makers across the UK, Ireland, France, Germany and the USA to find out about what the future holds. A responsible AI framework is going to be key. Read our report to learn more. Sponsored by: Cognizant and Microsoft |
Whitepaper Unlock the Future of Biotherapeutics with Catalent Biologics! Sponsored by: Catalent Biologics |
Whitepaper Finding an effective epilepsy treatment can be arduous. Download this brochure to delve into how IQVIA's expertise and innovative strategic approach can streamline the clinical trial process, helping to get new therapies to patients who need them sooner. Sponsored by: IQVIA |
Whitepaper Navigating the Path to Medication Adherence: Overcoming 8 Key Challenges Sponsored by: Quest Diagnostics |
Whitepaper Open up unexpected opportunities. This digital story offers pharma marketers proactive strategies for helping patients discover and switch to treatments, even if they aren’t actively looking to make a change. Sponsored by: Healthline Media |
Whitepaper Blood-based biomarker testing presents a promising solution to improve access to critical early risk assessment along with a pathway towards accelerated clinical trials for Alzheimer's Disease. Sponsored by: Quest Diagnostics |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| The Lighthouse at Pier 61 in New York City |
|
|
| |
|
